TE-1146 / T-E Pharma - LARVOL DELTA

Potent Effects of Lenalidomide-Conjugated Anti-CD38 Antibody-Drug Conjugate (TE-1146) on Multiple Myeloma Cells Isolated from Patients (ASH 2024) - "Studies have shown that TE-1146 has stronger direct cytotoxicity than the combination of daratumumab (Dara) and Len, while maintaining similar Fc-mediated effects such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP)...In subgroup 2 (patients who relapsed after bortezomib, thalidomide, and dexamethasone [VTD] regimens, without prior Dara/Len treatment), all 4 eligible samples exhibited a 100% cytotoxic response with a mean IC50 value of 0.02 nM...Nevertheless, in subgroup 3, TE-1146 showed limited efficacy, likely due to developed resistance to Dara or Len.Conclusion : This study demonstrates that TE-1146 enhanced direct cytotoxicity, significantly improving efficacy over the Dara/Len combination while potentially reducing the required dosage and associated side effects of Len. These results support further development and clinical evaluation of TE-1146 ADC as a promising..."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology • CTSB • SDC1

TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity. (PubMed, Haematologica) - "Not available."

Journal • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers. (PubMed, Adv Sci (Weinh)) - "TE-1146 precisely delivers lenalidomide to target CD38-overexpressing tumor cells. In contrast, lenalidomide without daratumumab cannot easily enter cells, whereas daratumumab without lenalidomide relies on Fc-dependent effector functions to kill tumor cells."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells (AACR 2023) - "Lenalidomide is extremely powerful in killing multiple myeloma cells if brought into the MM cells. It is estimated that a very minute amount, probably less than 0.01%, of intraperitoneally injected lenalidomide gets into the transplanted MM tumor in the mouse model. TE-1146 may be a more effective and less toxic drug than Daratumumab/Lenalidomide combination in treating patients with hard-to-treat MM."

Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor